Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 189

1.

Evidence and controversies on the role of XMRV in prostate cancer and chronic fatigue syndrome.

Menéndez-Arias L.

Rev Med Virol. 2011 Jan;21(1):3-17. doi: 10.1002/rmv.673. Epub 2010 Nov 26. Review.

PMID:
21294212
2.

Distribution of xenotropic murine leukemia virus-related virus (XMRV) infection in chronic fatigue syndrome and prostate cancer.

Mikovits JA, Huang Y, Pfost MA, Lombardi VC, Bertolette DC, Hagen KS, Ruscetti FW.

AIDS Rev. 2010 Jul-Sep;12(3):149-52. Review.

PMID:
20842203
3.

Lack of evidence for a role of xenotropic murine leukemia virus-related virus in the pathogenesis of prostate cancer and/or chronic fatigue syndrome.

Hong P, Li J.

Virus Res. 2012 Jul;167(1):1-7. doi: 10.1016/j.virusres.2012.04.004. Epub 2012 Apr 15. Review.

PMID:
22531412
4.

Xenotropic murine leukaemia virus-related virus (XMRV) does not cause chronic fatigue.

Robinson MJ, Erlwein O, McClure MO.

Trends Microbiol. 2011 Nov;19(11):525-9. doi: 10.1016/j.tim.2011.08.005. Epub 2011 Oct 4.

PMID:
21978843
5.

Prevalence of xenotropic murine leukemia virus-related virus infection in different risk populations in Spain.

Arredondo M, Hackett J Jr, de Bethencourt FR, Treviño A, Escudero D, Collado A, Qiu X, Swanson P, Soriano V, de Mendoza C.

AIDS Res Hum Retroviruses. 2012 Sep;28(9):1089-94. doi: 10.1089/AID.2011.0149. Epub 2012 Feb 21.

PMID:
22206583
6.

No association of xenotropic murine leukemia virus-related virus with prostate cancer or chronic fatigue syndrome in Japan.

Furuta RA, Miyazawa T, Sugiyama T, Kuratsune H, Ikeda Y, Sato E, Misawa N, Nakatomi Y, Sakuma R, Yasui K, Yamaguti K, Hirayama F.

Retrovirology. 2011 Mar 17;8:20. doi: 10.1186/1742-4690-8-20.

7.

XMRV: usage of receptors and potential co-receptors.

Setty MK, Devadas K, Ragupathy V, Ravichandran V, Tang S, Wood O, Gaddam DS, Lee S, Hewlett IK.

Virol J. 2011 Sep 6;8:423. doi: 10.1186/1743-422X-8-423.

8.

XMRV, prostate cancer and chronic fatigue syndrome.

Kenyon JC, Lever AM.

Br Med Bull. 2011;98:61-74. doi: 10.1093/bmb/ldr010. Epub 2011 May 6. Review.

PMID:
21551158
9.

The human retrovirus XMRV in prostate cancer and chronic fatigue syndrome.

Silverman RH, Nguyen C, Weight CJ, Klein EA.

Nat Rev Urol. 2010 Jul;7(7):392-402. doi: 10.1038/nrurol.2010.77. Epub 2010 Jun 1. Review.

PMID:
20517289
10.

Absence of xenotropic murine leukemia virus-related virus in blood donors in China.

Mi Z, Lu Y, Zhang S, An X, Wang X, Chen B, Wang Q, Tong Y.

Transfusion. 2012 Feb;52(2):326-31. doi: 10.1111/j.1537-2995.2011.03267.x. Epub 2011 Aug 19.

PMID:
21854397
11.

Xenotropic murine leukemia virus-related virus does not pose a risk to blood recipient safety.

Dodd RY, Hackett J Jr, Linnen JM, Dorsey K, Wu Y, Zou S, Qiu X, Swanson P, Schochetman G, Gao K, Carrick JM, Krysztof DE, Stramer SL.

Transfusion. 2012 Feb;52(2):298-306. doi: 10.1111/j.1537-2995.2011.03450.x. Epub 2011 Nov 21.

PMID:
22098340
12.

The xenotropic murine leukemia virus-related retrovirus debate continues at first international workshop.

Stoye JP, Silverman RH, Boucher CA, Le Grice SF.

Retrovirology. 2010 Dec 22;7:113. doi: 10.1186/1742-4690-7-113.

13.

Raltegravir is a potent inhibitor of XMRV, a virus implicated in prostate cancer and chronic fatigue syndrome.

Singh IR, Gorzynski JE, Drobysheva D, Bassit L, Schinazi RF.

PLoS One. 2010 Apr 1;5(4):e9948. doi: 10.1371/journal.pone.0009948.

14.

Xenotropic murine leukaemia virus-related virus is not found in peripheral blood cells from treatment-naive human immunodeficiency virus-positive patients.

Maggi F, Focosi D, Lanini L, Sbranti S, Mazzetti P, Macera L, Davini S, De Donno M, Mariotti ML, Antonelli G, Scatena F, Pistello M.

Clin Microbiol Infect. 2012 Feb;18(2):184-8. doi: 10.1111/j.1469-0691.2011.03580.x. Epub 2011 Jun 14.

15.

Is XMRV a causal virus for prostate cancer?

Zhang ZZ, Guo BF, Feng Z, Zhang L, Zhao XJ.

Asian J Androl. 2011 Sep;13(5):698-701. doi: 10.1038/aja.2011.32. Epub 2011 Jul 18. Review.

16.

Seroprevalence of xenotropic murine leukemia virus-related virus in normal and retrovirus-infected blood donors.

Qiu X, Swanson P, Tang N, Leckie GW, Devare SG, Schochetman G, Hackett J Jr.

Transfusion. 2012 Feb;52(2):307-16. doi: 10.1111/j.1537-2995.2011.03395.x. Epub 2011 Oct 24.

PMID:
22023235
17.

Inhibition of xenotropic murine leukemia virus-related virus by APOBEC3 proteins and antiviral drugs.

Paprotka T, Venkatachari NJ, Chaipan C, Burdick R, Delviks-Frankenberry KA, Hu WS, Pathak VK.

J Virol. 2010 Jun;84(11):5719-29. doi: 10.1128/JVI.00134-10. Epub 2010 Mar 24.

18.

Androgen-independent proliferation of LNCaP prostate cancer cells infected by xenotropic murine leukemia virus-related virus.

Kakoki K, Kamiyama H, Izumida M, Yashima Y, Hayashi H, Yamamoto N, Matsuyama T, Igawa T, Sakai H, Kubo Y.

Biochem Biophys Res Commun. 2014 Apr 25;447(1):216-22. doi: 10.1016/j.bbrc.2014.03.154. Epub 2014 Apr 8.

PMID:
24721431
19.

Integration site preference of xenotropic murine leukemia virus-related virus, a new human retrovirus associated with prostate cancer.

Kim S, Kim N, Dong B, Boren D, Lee SA, Das Gupta J, Gaughan C, Klein EA, Lee C, Silverman RH, Chow SA.

J Virol. 2008 Oct;82(20):9964-77. doi: 10.1128/JVI.01299-08. Epub 2008 Aug 6.

20.

Prevalence of human xenotropic murine leukemia virus-related gammaretrovirus (XMRV) in Dutch prostate cancer patients.

Verhaegh GW, de Jong AS, Smit FP, Jannink SA, Melchers WJ, Schalken JA.

Prostate. 2011 Mar 1;71(4):415-20. doi: 10.1002/pros.21255. Epub 2010 Sep 28.

PMID:
20878949

Supplemental Content

Support Center